

## PROFESSIONAL INFORMATION

### SCHEDULING STATUS

<b>S4</b>
-----------

#### 1 NAME OF THE MEDICINE

**EASAN** powder for solution for infusion

#### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial contains 245,3 mg of fosaprepitant dimeglumine equivalent to 150 mg of fosaprepitant free acid.

Contains sugar: lactose monohydrate 395 mg per vial.

For full list of excipients, see section 6.1

#### 3 PHARMACEUTICAL FORM

Powder for solution for infusion.

White or off-white block-shaped solid or powder.

#### 4 CLINICAL PARTICULARS

##### 4.1 Therapeutic indications

EASAN, in combination with other anti-emetic medicines, is indicated for the prevention of acute (0 to 24 hours) and delayed (> 24 to 120 hours) nausea and vomiting associated with initial and repeat courses of:

- highly emetogenic cancer chemotherapy (see Section 4.2).
- moderately emetogenic cancer chemotherapy (see Section 4.2).

##### 4.2 Posology and method of administration

###### Posology

EASAN powder for solution for infusion is a lyophilised pro-drug of aprepitant.

EASAN is administered on Day 1 as an infusion over 20 to 30 minutes initiated approximately 30 minutes prior to chemotherapy. EASAN should be administered in conjunction with a corticosteroid and a 5-HT<sub>3</sub> antagonist as specified in the tables below. The professional information for the co-administered 5-HT<sub>3</sub> antagonist must be consulted prior to initiation of treatment with EASAN.

Recommended dosing for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.

<b>Highly Emetogenic Chemotherapy Regimen</b>				
	Day 1	Day 2	Day 3	Day 4
EASAN	150 mg IV	None	None	None
Dexamethasone**	12 mg orally	8 mg orally	8 mg orally twice daily	8 mg orally twice daily
5-HT <sub>3</sub> antagonist	See the professional information for the selected 5-HT <sub>3</sub> antagonist for the appropriate dosing information.	None	None	None

\*\*Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. Dexamethasone should also be administered in the evenings on Days 3 and 4. The dose of dexamethasone accounts for interactions.

Recommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:

<b>Moderately Emetogenic Chemotherapy Regimen</b>	
	Day 1
EASAN	150 mg IV
Dexamethasone**	12 mg orally

5-HT <sub>3</sub> antagonist	See the professional information for the selected 5-HT <sub>3</sub> antagonist for the appropriate dosing information.
------------------------------	--

\*\*Dexamethasone should be administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for interactions.

### **General information**

See section 4.5 for additional information on the administration of EASAN with corticosteroids.

Refer to the full prescribing information for co-administered anti-emetic medicines.

No dosage adjustment is necessary for the elderly.

No dosage adjustment is necessary based on age, gender, race or Body Mass Index (BMI).

No dosage adjustment is necessary for patients with severe renal insufficiency (creatinine clearance < 30 ml/min) or for patients with end stage renal disease undergoing haemodialysis.

No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency (Child-Pugh score 5 to 9). There are no clinical data in patients with severe hepatic insufficiency (Child-Pugh > 9) (see Section 4.4).

### **Method of administration**

EASAN is for intravenous administration.

#### **For single use only.**

Discard any unused portion.

### **Preparation of EASAN for Infusion**

1. Inject 5 ml saline into the vial. Assure that saline is added to the vial along the vial wall in order to prevent foaming. Swirl the vial gently. Avoid shaking and jetting saline into the vial. After reconstitution, use only if the solution is a clear colourless

or pale yellow to yellow solution, free from visible particles.

2. Prepare an infusion bag filled with 145 ml of saline.

3. Withdraw the entire volume from the vial and transfer it into an infusion bag containing 145 ml of saline to yield a total volume of 150 ml. Gently invert the bag 2 to 3 times.

EASAN should be inspected visually for particulate matter and discolouration before administration whenever solution and container permit.

See section 6.2 for incompatibilities and section 6.4 for storage conditions after reconstitution and dilution.

### 4.3 Contraindications

- Hypersensitivity to aprepitant, polysorbate 80, or to any of the excipients (see section 6.1).
- Co-administration with pimozone, terfenadine, astemizole or cisapride. Inhibition of cytochrome P450 isoenzyme 3A4 (CYP3A4) by aprepitant could result in elevated plasma concentrations of these medicines potentially causing serious or life-threatening reactions. (see Section 4.5).
- Pregnancy and breastfeeding (see Section 4.6).
- Paediatric patients, as the safety and efficacy have not been established.

### 4.4 Special warnings and precautions for use

#### ***Patients with moderate to severe hepatic impairment***

There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. EASAN should be used with caution in these patients (see Section 5.2).

#### ***Severe hepatic insufficiency***

Severe hepatic insufficiency (Child-Pugh score > 9).

There are no clinical or pharmacokinetic data in patients with severe hepatic insufficiency. Caution should be exercised when EASAN is administered in these patients.

Since EASAN is rapidly converted to aprepitant (a weak to moderate inhibitor of CYP3A4), EASAN should be used with caution in patients receiving concomitant medicines that are primarily metabolised through CYP3A4; some chemotherapy medicines are metabolised by CYP3A4 (see section 4.5).

Weak inhibition of CYP3A4 by EASAN could result in elevated plasma concentrations of these concomitant medicines (see section 4.5). Concomitant administration of EASAN with strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution. The effect of oral aprepitant on the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of oral aprepitant on the pharmacokinetics of intravenously administered CYP3A4 substrates (see section 4.5).

### ***CYP3A4 interactions***

EASAN should be used with caution in patients receiving concomitant active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as ciclosporin, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see Section 4.5). Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.

### ***Co-administration with warfarin (a CYP2C9 substrate)***

In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely for 14 days, particularly at 7 to 10 days following the use of EASAN with each chemotherapy cycle (see section 4.5).

***Co-administration with hormonal contraceptives***

The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of EASAN. Alternative non-hormonal back-up methods of contraception should be used during treatment with EASAN and for 2 months following the use of EASAN (see section 4.5).

***Hypersensitivity reactions***

Immediate hypersensitivity reactions including flushing, erythema, dyspnoea, and anaphylaxis/anaphylactic shock have occurred during or soon after infusion of fosaprepitant (as in EASAN). These hypersensitivity reactions have generally responded to discontinuation of the infusion and administration of appropriate therapy. It is not recommended to reinitiate the infusion in patients who experience hypersensitivity reactions.

***Administration and infusion site reactions***

Infusion site reactions (ISRs) have been reported with the use of EASAN (see section 4.8). The majority of severe ISRs, including thrombophlebitis and vasculitis, were reported with concomitant vesicant (e.g., anthracycline-based) chemotherapy administration, particularly when associated with extravasation. Necrosis was also reported in some patients with concomitant vesicant chemotherapy. Mild injection site thrombosis has been observed at higher doses without concomitant vesicant chemotherapy.

EASAN should not be given as a bolus injection, but should always be diluted and given as a slow intravenous infusion. EASAN should not be administered intramuscularly or subcutaneously. If signs or symptoms of local irritation occur, the injection or infusion should be terminated and restarted in another vein.

***Excipient warning***

Contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not receive EASAN.

**4.5 Interaction with other medicines and other forms of interaction**

When administered intravenously fosaprepitant is rapidly converted to aprepitant. EASAN, given as a single dose, is a weak inhibitor of CYP3A4. Fosaprepitant (as in EASAN) does not seem to interact with the P-glycoprotein transporter, as demonstrated by the lack of interaction of oral aprepitant with digoxin. It is anticipated that fosaprepitant would cause less or no greater induction of CYP2C9, CYP3A4 and glucuronidation than that caused by the administration of oral aprepitant. Data are lacking regarding effects on CYP2C8 and CYP2C19.

Interactions with other medicines following administration of intravenous fosaprepitant (as in EASAN) are likely to occur with active substances that interact with oral aprepitant.

The following information was derived from studies conducted with oral aprepitant and studies conducted with intravenous single-dose fosaprepitant co-administered with dexamethasone, midazolam, or diltiazem.

**Effect of fosaprepitant on the pharmacokinetics of other active substances*****CYP3A4 inhibition***

As a weak inhibitor of CYP3A4, the fosaprepitant (as in EASAN) 150 mg single dose can cause a transient increase in plasma concentrations of co-administered active substances that are metabolised through CYP3A4. The total exposure of CYP3A4 substrates may increase up to 2-fold on Days 1 and 2 after co-administration with a single 150 mg fosaprepitant dose. EASAN must not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of

CYP3A4 by fosaprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life-threatening reactions. (see Section 4.3). Caution is advised during concomitant administration of EASAN and active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as ciclosporin, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, and quinidine (see Section 4.4).

### ***Corticosteroids***

**Dexamethasone:** The oral dexamethasone dose should be reduced by approximately 50 % when co-administered with fosaprepitant (see section 4.2). Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the  $AUC_{0-24hr}$  of dexamethasone, a CYP3A4 substrate, by 100 % on Day 1, 86 % on Day 2 and 18 % on Day 3 when dexamethasone was co-administered as a single 8 mg oral dose on Days 1, 2, and 3.

**Methylprednisolone:** Oral aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1,3-fold on Day 1 and by 2,5-fold on Day 3, when methylprednisolone was co-administered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.

### ***Chemotherapeutic medicines***

Interaction studies with fosaprepitant 150 mg and chemotherapeutic medicines have not been conducted; however, based on studies with oral aprepitant and docetaxel and vinorelbine, EASAN is not expected to have a clinically relevant interaction with intravenously administered docetaxel and vinorelbine. An interaction with orally administered chemotherapeutic medicines metabolised primarily or partly by CYP3A4 (e.g., etoposide, vinorelbine) cannot be excluded.

Caution is advised and additional monitoring may be appropriate in patients receiving medicines metabolised primarily or partly by CYP3A4 (see section 4.4). Post-marketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have been reported after aprepitant and ifosfamide co-administration.

### ***Immunosuppressants***

Following a single 150 mg fosaprepitant dose, a transient moderate increase for two days possibly followed by a mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (e.g. ciclosporin, tacrolimus, everolimus and sirolimus) is expected. Given the short duration of increased exposure, dose reduction of the immunosuppressant based on Therapeutic Dose Monitoring is not recommended on the day of and the day after administration of EASAN.

### ***Midazolam***

Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the AUC<sub>0-∞</sub> of midazolam by 77 % on Day 1 and had no effect on Day 4 when midazolam was co-administered as a single oral dose of 2 mg on Days 1 and 4. Fosaprepitant 150 mg is a weak CYP3A4 inhibitor as a single dose on Day 1 with no evidence of inhibition or induction of CYP3A4 observed on Day 4.

The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicines with EASAN.

### ***Diltiazem***

Interaction studies with fosaprepitant 150 mg and diltiazem have not been conducted; however, the following study with 100 mg of fosaprepitant should be considered when using EASAN with diltiazem. In patients with mild to moderate

hypertension, infusion of 100 mg of fosaprepitant over 15 minutes with diltiazem 120 mg 3 times daily, resulted in a 1,4-fold increase in diltiazem AUC and a small but clinically meaningful decrease in blood pressure, but did not result in a clinically meaningful change in heart rate, or PR interval.

### ***Induction***

The fosaprepitant 150 mg single dose did not induce CYP3A4 on Days 1 and 4 in the midazolam interaction study. It is anticipated that EASAN would cause less or no greater induction of CYP2C9, CYP3A4, and glucuronidation than that caused by the administration of the 3-day oral aprepitant regimen, for which a transient induction with its maximum effect 6-8 days after first aprepitant dose has been observed. The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations. Data are lacking regarding effects on CYP2C8 and CYP2C19. Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered with EASAN.

### ***Warfarin***

In patients on chronic warfarin therapy, the prothrombin time (INR) should be monitored closely during treatment with and for 14 days following the use of EASAN for the prevention of chemotherapy induced nausea and vomiting (see section 4.4).

### ***Hormonal contraceptives***

The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of fosaprepitant. Alternative non-hormonal back-up methods

of contraception should be used during treatment with fosaprepitant and for 2 months following the use of fosaprepitant.

### **5-HT<sub>3</sub> antagonists**

Interaction studies with fosaprepitant 150 mg and 5-HT<sub>3</sub> antagonists have not been conducted; however, in clinical interaction studies, the oral aprepitant regimen did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron). Therefore, there is no evidence of interaction with the use of EASAN and 5-HT<sub>3</sub> antagonists.

### **Effect of other medicines on the pharmacokinetics of aprepitant**

Concomitant administration of fosaprepitant with active substances that inhibit CYP3A4 activity (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected to result in several-fold increased plasma concentrations of aprepitant (see Section 4.4). Ketoconazole increased the terminal half-life of oral aprepitant about 3-fold.

Concomitant administration of fosaprepitant with active substances that strongly induce CYP3A4 activity (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination could result in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy.

Concomitant administration of fosaprepitant with herbal preparations containing St. John's Wort (*Hypericum perforatum*) is not recommended. Rifampicin decreased the mean terminal half-life of oral aprepitant by 68 %.

### **Paediatric population**

Interaction studies have only been performed in adults.

## **4.6 Fertility, pregnancy and lactation**

### ***Contraception in males and females***

The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of EASAN. Alternative non-hormonal back-up methods of contraception should be used during treatment with EASAN and for 2 months following the last dose of EASAN (see Sections 4.4 and 4.5).

### **Pregnancy**

Safety in pregnancy has not been established.

EASAN should not be used during pregnancy.

### **Breastfeeding**

Aprepitant is excreted in the milk of lactating rats after intravenous administration of fosaprepitant as well as after oral administration of aprepitant. It is not known whether aprepitant is excreted in human milk. Therefore, breastfeeding is not recommended during treatment with EASAN.

### **Fertility**

The potential for effects of fosaprepitant and aprepitant on fertility has not been fully characterised because exposure levels above the therapeutic exposure in humans could not be attained in animal studies. These fertility studies did not indicate direct or indirect harmful effects with respect to mating performance, fertility, embryonic/foetal development, or sperm count and motility.

## **4.7 Effects on ability to drive and use machines**

EASAN may affect the patient's ability to drive and use machines. Dizziness and fatigue may occur following administration of EASAN (see section 4.8).

## 4.8 Undesirable effects

### a. Summary of the safety profile

Since fosaprepitant is converted to aprepitant, those adverse experiences associated with aprepitant are also expected to occur with EASAN.

The overall safety of fosaprepitant was evaluated in 1 143 individuals, and the overall safety of oral aprepitant was evaluated in approximately 6 500 individuals.

#### *Oral aprepitant*

The most frequent adverse reactions reported at a greater incidence in adults treated with the aprepitant regimen than with standard therapy in patients receiving HEC were: hiccups (4,6 % versus 2,9 %), alanine aminotransferase (ALT) increased (2,8 % versus 1,1 %), dyspepsia (2,6 % versus 2,0 %), constipation (2,4 % versus 2,0 %), headache (2,0 % versus 1,8 %), and decreased appetite (2,0 % versus 0,5 %). The most frequent adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving MEC was fatigue (1,4 % versus 0,9 %).

### b. Tabulated summary of adverse reactions - aprepitant

The following adverse reactions were observed in a pooled analysis of the HEC and MEC studies at a greater incidence with oral aprepitant than with standard therapy in patients or in post-marketing use. The frequency categories given in the table are based on the studies in adults; the observed frequencies in the paediatric studies were similar or lower, unless shown in the table. Some less frequent ADRs in the adult population were not observed in the paediatric studies. Frequencies are defined as: frequent; less frequent and frequency unknown (cannot be estimated from the available data).

<b>MedDRA system organ class</b>	<b>Frequency</b>	<b>Adverse reactions</b>
Infections and infestations	Less frequent	Candidiasis, staphylococcal infection
Blood and lymphatic system disorders	Less frequent	Febrile neutropenia, anaemia
Immune system disorders	Frequency unknown	Hypersensitivity reactions including anaphylactic reactions
Metabolism and nutrition disorders	Frequent	Decreased appetite
	Less frequent	Polydipsia
Psychiatric disorders	Less frequent	Anxiety, disorientation, euphoric mood
Nervous system disorders	Frequent	Headache
	Less frequent	Dizziness, somnolence, cognitive disorder, lethargy, dysgeusia
Eye disorders	Less frequent	Conjunctivitis
Ear and labyrinth disorders	Less frequent	Tinnitus
Cardiac disorders	Less frequent	Palpitations, bradycardia, cardiovascular disorder
Vascular disorders	Less frequent	Hot flush/flushing
Respiratory, thoracic and mediastinal disorders	Frequent	Hiccups
	Less frequent	Oropharyngeal pain, sneezing, cough, postnasal drip, throat irritation

<b>MedDRA system organ class</b>	<b>Frequency</b>	<b>Adverse reactions</b>
Gastrointestinal disorders	Frequent	Constipation, dyspepsia
	Less frequent	Eructation, nausea*, vomiting*, gastroesophageal reflux disease, abdominal pain, dry mouth, flatulence, duodenal ulcer perforation, stomatitis, abdominal distension, faeces hard, neutropenic colitis
Skin and subcutaneous tissue disorders	Less frequent	Rash, acne, photosensitivity reaction, hyperhidrosis, seborrhoea, skin lesion, rash pruritic, Stevens-Johnson syndrome/toxic epidermal necrolysis
	Frequency unknown	Pruritus, urticaria
Musculoskeletal and connective tissue disorders	Less frequent	Muscular weakness, muscle spasms
Renal and urinary disorders	Less frequent	Dysuria, pollakiuria
General disorders and administration site conditions	Frequent	Fatigue
	Less frequent	Asthenia, malaise, oedema, chest discomfort, gait disturbance
Investigations	Frequent	Increased ALT

MedDRA system organ class	Frequency	Adverse reactions
	Less frequent	Increased AST, increased blood alkaline phosphatase, red blood cells urine positive, decreased blood sodium, decreased weight, decreased neutrophil count, glucose urine present, increased urine output

\*Nausea and vomiting were efficacy parameters in the first 5-days of post-chemotherapy treatment and were reported as adverse reactions only thereafter.

### c. Description of selected adverse reactions

The adverse reactions profiles in the Multiple-Cycle extension of HEC and MEC studies in adults for up to 6 additional cycles of chemotherapy were generally similar to those observed in Cycle 1.

In an additional active-controlled clinical study in 1,169 adult patients receiving aprepitant and HEC, the adverse reactions profile was generally similar to that seen in the other HEC studies with aprepitant.

Additional adverse reactions were observed in adult patients treated with aprepitant for post-operative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation\*, dysarthria, dyspnoea, hyposensitivity, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus\*, visual acuity reduced, wheezing.

\*Reported in patients taking a higher dose of aprepitant.

***Fosaprepitant***

In an active-controlled clinical study in adult patients receiving HEC, safety was evaluated for 1 143 patients receiving the 1-day regimen of fosaprepitant 150 mg compared to 1 169 patients receiving the 3-day regimen of aprepitant. Additionally, in a placebo-controlled clinical trial in adult patients receiving MEC, safety was evaluated for 504 patients receiving a single dose of fosaprepitant 150 mg compared to 497 patients receiving the control regimen.

In a pooled analysis of 3 active-controlled clinical studies in paediatric patients (aged 6 months to 17 years) receiving either HEC or MEC and a single dose of fosaprepitant at or above the recommended 1-day regimen dose, safety was evaluated for 139 patients receiving the 1-day regimen of fosaprepitant. In the same analysis, safety was evaluated for 199 patients receiving either HEC or MEC and a single dose of fosaprepitant at or above the recommended 3-day regimen of fosaprepitant. Safety data following the administration of the 3-day IV/oral/oral regimen were also included.

No data are available following the administration of a 3-day IV fosaprepitant regimen in paediatric patients. The safety profile of the 3-day IV fosaprepitant regimen in paediatric patients is expected to be similar to that of the 1-day fosaprepitant regimen as the low daily trough levels do not significantly increase the exposures on subsequent days.

The safety profile of fosaprepitant in adult and paediatric patients was generally similar to that observed with aprepitant.

**Tabulated list of adverse reactions – fosaprepitant**

The following are adverse reactions reported in adult patients receiving fosaprepitant in clinical studies or post-marketing that have not been reported with aprepitant as described above. The frequency categories in the table are based on studies in adults; the observed frequencies in the paediatric studies were similar

or lower. Some adverse reactions that are frequently observed in the adult population were not observed in the paediatric studies. Infusion site reactions (ISRs) have been reported with the use of fosaprepitant (see section 4.4).

<b>MedDRA system organ class</b>	<b>Frequency</b>	<b>Adverse reactions</b>
Immune system disorders	Frequency unknown	Hypersensitivity reactions including anaphylactic reactions/ anaphylactic shock
Vascular disorders	Less frequent	Flushing, thrombophlebitis (predominantly, infusion-site thrombophlebitis)
Skin and subcutaneous tissue disorders	Less frequent	Erythema, pruritus, rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis
General disorders and administration site conditions	Less frequent	Infusion site erythema, infusion site pain, infusion site pruritus, infusion site induration
	Frequency unknown	Immediate hypersensitivity reactions including flushing, erythema, dyspnoea, anaphylactic reactions/ anaphylactic shock
Investigations	Less frequent	Increased blood pressure

#### *Reporting of suspected adverse reactions*

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the

medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the “**6.04 Adverse Drug Reactions Reporting Form**”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>.

#### **4.9 Overdose**

In the event of overdose, EASAN should be discontinued and general supportive treatment and monitoring should be provided.

Aprepitant cannot be removed by haemodialysis.

### **5 PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antiemetics and antinauseants, ATC code: A04AD12

Pharmacological classification: A.5.7.2 Anti-emetics and antivertigo preparations

Fosaprepitant dimeglumine is a pro-drug of aprepitant. When administered intravenously it is rapidly converted to aprepitant, a substance P neurokinin 1 (NK<sub>1</sub>) receptor antagonist. Its anti-emetic effects are attributable to aprepitant.

NK<sub>1</sub>-receptor antagonists inhibit emesis induced by cytotoxic chemotherapeutic medicines, such as cisplatin, via central actions. Human Positron Emission Tomography (PET) studies with aprepitant have shown that it penetrates the brain and occupies brain NK<sub>1</sub> receptors.

#### **5.2 Pharmacokinetic properties**

Fosaprepitant, a pro-drug of aprepitant, when administered intravenously is rapidly converted to aprepitant. Plasma concentrations of fosaprepitant are below quantifiable levels within 30 minutes of the completion of infusion.

### **Aprepitant after fosaprepitant administration**

Following a single intravenous 150 mg dose of fosaprepitant administered as a 20-minute infusion to healthy adult volunteers, the mean  $AUC_{0-\infty}$  of aprepitant was 35,0  $\mu\text{g}\cdot\text{hr}/\text{ml}$  and the mean maximal aprepitant concentration was 4,01  $\mu\text{g}/\text{ml}$ .

### **Distribution**

Aprepitant is highly protein bound, with a mean of 97 %. The geometric mean volume of distribution at steady state ( $V_{d_{ss}}$ ) of aprepitant estimated from a single 150 mg intravenous dose of fosaprepitant is approximately 82 L in humans.

Aprepitant crosses the placenta and blood brain barrier.

### **Biotransformation**

Fosaprepitant was rapidly converted to aprepitant in *in vitro* incubations with liver preparations from humans. Furthermore, fosaprepitant underwent rapid and nearly complete conversion to aprepitant in S9 preparations from other human tissues including kidney, lung and ileum. Thus, it appears that the conversion of fosaprepitant to aprepitant can occur in multiple tissues. In humans, fosaprepitant administered intravenously was rapidly converted to aprepitant within 30 minutes following the end of infusion.

Aprepitant undergoes extensive metabolism. In healthy young adults, aprepitant accounts for approximately 19 % of the radioactivity in plasma over 72 hours following a single intravenous administration 100 mg dose of [ $^{14}\text{C}$ ]- fosaprepitant, a pro-drug for aprepitant, indicating a substantial presence of metabolites in the plasma. Twelve metabolites of aprepitant have been identified in human plasma. The metabolism of aprepitant occurs largely via oxidation at the morpholine ring and its side chains and the resultant metabolites were only weakly active. In vitro studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and

CYP2C19.

All metabolites observed in urine, faeces and plasma following an intravenous 100 mg [<sup>14</sup>C]-fosaprepitant dose were also observed following an oral dose of [<sup>14</sup>C]-aprepitant. Upon conversion of 245,3 mg of fosaprepitant dimeglumine (equivalent to 150 mg fosaprepitant) to aprepitant, 23,9 mg of phosphoric acid and 95,3 mg of meglumine are liberated.

### **Elimination**

Aprepitant is not excreted unchanged in urine. Metabolites are excreted in urine and via biliary excretion in faeces. Following a single intravenously administered 100 mg dose of [<sup>14</sup>C]- fosaprepitant to healthy subjects, 57 % of the radioactivity was recovered in urine and 45 % in faeces.

The pharmacokinetics of aprepitant is non-linear across the clinical dose range. The terminal half-life of aprepitant following a 150 mg intravenous dose of fosaprepitant was approximately 11 hours. The geometric mean plasma clearance of aprepitant following a 150 mg intravenous dose of fosaprepitant was approximately 73 ml/min.

### **Pharmacokinetics in special populations**

**Hepatic impairment:** Fosaprepitant is metabolised in various extrahepatic tissues; therefore hepatic impairment is not expected to alter the conversion of fosaprepitant to aprepitant. Mild hepatic impairment (Child-Pugh class A) does not affect the pharmacokinetics of aprepitant to a clinically relevant extent. No dose adjustment is necessary for patients with mild hepatic impairment. Conclusions regarding the influence of moderate hepatic impairment (Child-Pugh class B) on aprepitant pharmacokinetics cannot be drawn from available data. There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh class C).

**Renal impairment:** A single 240 mg dose of oral aprepitant was administered to patients with severe renal impairment ( $\text{CrCl} < 30 \text{ ml/min}$ ) and to patients with end stage renal disease (ESRD) requiring haemodialysis.

In patients with severe renal impairment, the  $\text{AUC}_{0-\infty}$  of total aprepitant (unbound and protein bound) decreased by 21 % and  $\text{C}_{\text{max}}$  decreased by 32 %, relative to healthy subjects. In patients with ESRD undergoing haemodialysis, the  $\text{AUC}_{0-\infty}$  of total aprepitant decreased by 42 % and  $\text{C}_{\text{max}}$  decreased by 32 %. Due to modest decreases in protein binding of aprepitant in patients with renal disease, the AUC of pharmacologically active unbound aprepitant was not significantly affected in patients with renal impairment compared with healthy subjects. Haemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0,2 % of the dose was recovered in the dialysate.

No dose adjustment is necessary for patients with renal impairment or for patients with ESRD undergoing haemodialysis.

### Paediatric population

Fosaprepitant has not been evaluated in patients below 18 years of age (see Section 4.3).

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Edetate disodium (E386)

Lactose monohydrate

Polysorbate 80 (E433)

Hydrochloric acid (for pH adjustment)

Sodium hydroxide (for pH adjustment)

Water for injection

## 6.2 Incompatibilities

EASAN is incompatible with any solutions containing divalent cations (e.g.  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ ), including Hartman's and Lactated Ringer's Solution. EASAN must not be reconstituted or mixed with solutions for which physical and chemical compatibility have not been established.

## 6.3 Shelf life

36 months.

## 6.4 Special precautions for storage

Store in a refrigerator (2 – 8 °C).

The reconstituted final medicine solution is stable for 24 hours at ambient room temperature (at or below 25 °C) and should be used within 24 hours after reconstitution. If not used immediately, in-use storage times should not be longer than 24 hours at 2 to 8 °C.

## 6.5 Nature and contents of container

10 ml colourless transparent injection vials made of neutral borosilicate glass tubing, with grey rubber closure and aluminium cap.

Pack size: one vial per cardboard carton.

## 6.6 Special precautions for disposal and other handling

Any unused medicine or waste material should be disposed of in accordance with local requirements.

## 7 HOLDER OF CERTIFICATE OF REGISTRATION

**Kahma Biotech (Pty) Ltd**

106, 16th Road

Midrand

**8 REGISTRATION NUMBER**

550659

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

7 March 2023

**10 DATE OF REVISION OF THE TEXT**

A handwritten signature in black ink, appearing to be the initials 'Rd' or similar, located at the bottom right of the page.